Combined Treatment for Advanced Pancreatic Cancer
Author Information
Author(s): FJ Prott, K Schonekaes, P Preusser, K Ostkamp, W Wagner, 0 Micke, R Potter, U Sulkowski, C Rube, T Berns, N Willich
Primary Institution: University of Munster, Medical School, Monster, Germany
Hypothesis
Can combined modality treatment with accelerated radiotherapy and chemotherapy improve survival in patients with locally advanced inoperable pancreatic cancer?
Conclusion
The combined treatment of accelerated hyperfractionated radiotherapy and chemotherapy is feasible and improves median survival time for patients with locally advanced pancreatic cancer.
Supporting Evidence
- The median survival time for patients was 12.7 months, compared to 3-7 months after palliative surgery.
- The median progression-free interval was 6.6 months.
- Severe side effects occurred in 9.3% of patients.
Takeaway
Doctors tried a new way to treat patients with a tough kind of pancreatic cancer, and it helped them live longer than usual.
Methodology
Patients received hyperfractionated radiotherapy and chemotherapy with 5-fluorouracil and folinic acid over a period of less than 3 weeks.
Limitations
The study had a small sample size and was a feasibility study, which may limit the generalizability of the results.
Participant Demographics
11 women and 21 men, median age 62.3 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website